Parsons Capital Management’s AbbVie ABBV Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q2
$25M Sell
99,302
-10,685
-10% -$2.3M 1.13% 17
2026
Q1
$23.9M Buy
109,987
+24,096
+28% +$5.35M 1.09% 17
2025
Q4
$19.6M Buy
85,891
+2,071
+2% +$472K 1.08% 18
2025
Q3
$19.4M Buy
83,820
+577
+0.7% +$117K 1.1% 15
2025
Q2
$15.5M Sell
83,243
-23,916
-22% -$4.44M 0.95% 18
2025
Q1
$22.5M Sell
107,159
-4,231
-4% -$823K 1.23% 14
2024
Q4
$19.8M Buy
111,390
+18,865
+20% +$3.47M 1.07% 17
2024
Q3
$18.3M Sell
92,525
-285
-0.3% -$53.2K 1.16% 16
2024
Q2
$15.9M Sell
92,810
-105
-0.1% -$17.4K 1.08% 17
2024
Q1
$16.9M Sell
92,915
-798
-0.9% -$138K 1.16% 15
2023
Q4
$14.5M Buy
93,713
+2,970
+3% +$433K 1.04% 17
2023
Q3
$13.5M Buy
90,743
+132
+0.1% +$19.4K 1.07% 17
2023
Q2
$12.2M Buy
90,611
+223
+0.2% +$32.7K 0.93% 18
2023
Q1
$14.4M Sell
90,388
-3,086
-3% -$472K 1.16% 12
2022
Q4
$15.1M Buy
93,474
+2,030
+2% +$311K 1.26% 12
2022
Q3
$12.3M Buy
91,444
+12,779
+16% +$1.83M 1.1% 16
2022
Q2
$12M Sell
78,665
-5,339
-6% -$816K 1.08% 15
2022
Q1
$13.6M Buy
84,004
+1,105
+1% +$161K 1.03% 15
2021
Q4
$11.2M Buy
82,899
+250
+0.3% +$29.5K 0.8% 23
2021
Q3
$8.91M Buy
82,649
+2,546
+3% +$291K 0.7% 28
2021
Q2
$9.02M Buy
80,103
+455
+0.6% +$51.2K 0.69% 30
2021
Q1
$8.62M Buy
79,648
+5,712
+8% +$611K 0.71% 26
2020
Q4
$7.92M Buy
73,936
+10,114
+16% +$972K 0.68% 28
2020
Q3
$5.59M Sell
63,822
-520
-0.8% -$49K 0.55% 40
2020
Q2
$6.32M Buy
64,342
+1,770
+3% +$156K 0.67% 34
2020
Q1
$4.77M Sell
62,572
-9,255
-13% -$788K 0.61% 39
2019
Q4
$6.36M Sell
71,827
-209
-0.3% -$17.4K 0.64% 35
2019
Q3
$5.46M Sell
72,036
-2,515
-3% -$172K 0.59% 41
2019
Q2
$5.42M Sell
74,551
-1,197
-2% -$94.1K 0.59% 39
2019
Q1
$6.11M Sell
75,748
-3,525
-4% -$288K 0.67% 32
2018
Q4
$7.31M Sell
79,273
-1,042
-1% -$91.6K 0.9% 24
2018
Q3
$7.6M Buy
80,315
+113
+0.1% +$10.7K 0.8% 24
2018
Q2
$7.43M Sell
80,202
-221
-0.3% -$21.6K 0.84% 23
2018
Q1
$7.61M Buy
80,423
+285
+0.4% +$31.3K 0.89% 22
2017
Q4
$7.75M Sell
80,138
-543
-0.7% -$51.2K 0.86% 21
2017
Q3
$7.17M Buy
80,681
+1,163
+1% +$88.5K 0.85% 23
2017
Q2
$5.77M Sell
79,518
-218
-0.3% -$14.7K 0.7% 32
2017
Q1
$5.2M Sell
79,736
-431
-0.5% -$27.1K 0.66% 37
2016
Q4
$5.02M Buy
80,167
+601
+0.8% +$36.7K 0.67% 37
2016
Q3
$5.02M Sell
79,566
-463
-0.6% -$30K 0.68% 37
2016
Q2
$4.96M Sell
80,029
-1,855
-2% -$113K 0.67% 39
2016
Q1
$4.68M Sell
81,884
-241
-0.3% -$13.4K 0.64% 40
2015
Q4
$4.87M Buy
82,125
+352
+0.4% +$20.3K 0.68% 38
2015
Q3
$4.45M Buy
81,773
+310
+0.4% +$20.2K 0.65% 40
2015
Q2
$5.47M Buy
81,463
+322
+0.4% +$21K 0.73% 27
2015
Q1
$4.75M Sell
81,141
-19,443
-19% -$1.17M 0.67% 33
2014
Q4
$6.58M Sell
100,584
-1,400
-1% -$88.3K 0.87% 21
2014
Q3
$5.89M Buy
101,984
+545
+0.5% +$30.3K 0.82% 26
2014
Q2
$5.72M Sell
101,439
-530
-0.5% -$27.8K 0.79% 26
2014
Q1
$5.24M Buy
101,969
+16,281
+19% +$823K 0.75% 26
2013
Q4
$4.53M Sell
85,688
-530
-0.6% -$26K 0.68% 38
2013
Q3
$3.85M Sell
86,218
-14,238
-14% -$631K 0.63% 38
2013
Q2
$4.15M Buy
+100,456
New +$4.39M 0.71% 33

Other funds holding ABBV

Parsons Capital Management's ABBV Position: Q2 2026 in Review

Parsons Capital Management reduced its AbbVie (ABBV) stake by 9.7% in Q2 2026, selling an estimated $2.3M and leaving 99,302 shares worth $25M. The position accounts for 1.13% of the portfolio, ranked #17.

Parsons Capital Management first reported a position in ABBV in Q2 2013 and has held it in 53 quarters since. 2,841 funds tracked by Wall St. Rank hold ABBV as of Q2 2026.

  • Parsons Capital Management held 99,302 shares of AbbVie worth $25M as of Q2 2026.
  • Parsons Capital Management sold 10,685 AbbVie shares in Q2 2026, an estimated $2.3M.
  • AbbVie made up 1.13% of Parsons Capital Management's portfolio in Q2 2026, its #17 holding.
  • Parsons Capital Management first reported a position in AbbVie in Q2 2013 and has held it in 53 quarters since.
  • 2,841 funds tracked by Wall St. Rank held AbbVie as of Q2 2026.

Based on Parsons Capital Management's 13F filing for Q2 2026, filed 24 Jul 2026.